A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
Phase 3
Completed
- Conditions
- Hyperlipidemia
- Registration Number
- NCT00138762
- Lead Sponsor
- Pfizer
- Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
- Detailed Description
For additional information please call: 1-800-718-1021
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3800
Inclusion Criteria
- subjects with elevated cholesterol
Exclusion Criteria
- Women who are pregnant or lactating, or planning to become pregnant.
- Intolerance to statin therapy resulting in withdrawal
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method LDL and HDL levels
- Secondary Outcome Measures
Name Time Method other lipid parameters
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇬🇧Warminster, Wiltshire, United Kingdom